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Editorial
Common Molecular Challenges in Glaucoma
Mansoor Sarfarazi, PhD
Molecular Ophthalmic Genetics Laboratory, Department of Surgery, University of Connecticut Health Center, Farmington, CT, USA

J Ophthalmic Vis Res 2015; 10 (2): 95-97.

The clinical entity collectively known as glaucoma is a
very specific optic neuropathy that affects individuals
with various degrees of ocular complications and
even with greater degrees of genetic heterogeneity.[1,2]
Although the very first genetic contribution to this group
of eye disorders was described over 50 years ago,[3] it took
another 30 years before the first molecular studies of this
condition were undertaken.[4,5] The significant challenge
in understanding the basic underlying genes, proteins,
biochemical and molecular pathways that are involved
in this group of disorders is due to many difficulties in
accurate clinical diagnosis, classification, primary vs.
secondary disease, as well as various degrees of both
clinical and genetic heterogeneity.[6,7] Furthermore, lack
of suitable large families, extreme ages of onset, racial
ethnicity and many other limiting factors compound
our ability to find the majority of defective genes and
proteins for this ocular condition.
It is against this background that finding or even
relating certain mutations in one or more genes and their
possible contributions to a specific form of glaucoma
would be a significant addition to our understanding
of the molecular basis of this condition. One such study
is the current paper by Safari et al[8] in which they studied
the possible role of the LTBP2 gene in the etiology of
primary angle closure glaucoma (PACG) as well as
a single case with both PACG and pseudoexfoliation
glaucoma (PXFG). Although the LTBP2 gene was
originally reported to be the cause of primary congenital
glaucoma (PCG) in certain Pakistani[9] and Iranian[10]
families, subsequent studies by other investigators
failed to confirm this observation in a group of
American [11,12] Turkish, [12] English, [12] Indian [13] and
Saudi Arabian[14] PCG subjects. It is likely that the
congenital glaucoma nature of patients reported in the
earlier studies[9,10] were in fact of a secondary nature,
as those patients had a series of other ocular and
non‑ocular complications. Moreover, many other LTBP2
mutations have now been reported in megalocornea,[15]
spherophakia,[15] microspherophakia,[15,16] ectopia lentis[17]
and Weill‑Marchesani syndrome.[18] Interestingly, often
these disorders are reported with secondary forms of
glaucoma. Also, it has recently been reported that other

LTBP2 sequence variations may contribute to the etiology
of primary open angle glaucoma (POAG) and PXFG.[19]
In the current paper by Safari et al[8] the authors
investigated the possibility of LTBP2 involvement in
a group of PACG subjects. They sequenced a total of
54 PACG subjects for this gene and identified a number
of interesting sequence variations. After careful scrutiny
of the observed DNA variations, they concluded that
2 of the original 24 sequence changes may contribute to
the disease status of one subject with PACG and another
with both PACG and PXFG (Q1417R and G1660W,
respectively). This is the first systematic investigation
of LTBP2 gene mutations in a group of PACG subjects.
Although this is a very interesting report, one has to
note that the same two mutations of Q1417R and G1660W
are also identified in the South Asian subjects, though
no specific clinical manifestation has been reported for
these individuals. For Q1417R (rs137854863), the ExAC
Browser[20] reports 6 out of 16,506 South Asians and one
out of 66,148 Europeans to have the same mutation. For
G1660W (rs147223742), the comparable frequencies are
64 out of 16,512 South Asians and 1 out of 902 subjects
from other unspecified populations. It is very interesting
that these two mutations are reported primarily in
South Asian populations with a known high frequency
of PACG, as compared to other regions. Therefore, it is
likely that the two mutations reported by Sarafi et al[8]
are possibly involved in the PACG phenotype. However,
ultimate proof for such observation can only be
demonstrated by proper functional studies of these two
mutations.
It is equally likely that LTBP2 mutations will
be reported for many other ocular and non‑ocular
conditions. Experience from exome sequencing data on
over 60,000 individuals[20] now clearly shows that many
such individual mutations are present in other clinical
entities and in other ethnically related individuals.
Furthermore, as during exome or whole‑genome
sequencing over 25,000 genes are being simultaneously
sequenced, for any given subject, hundreds of individual
unique and previously unreported DNA variations
are often observed. Therefore, the task of relating
each of these uniquely observed DNA variations to a
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specific clinical phenotype of an individual remains
a significant challenge. Different uniquely‑identified
gene mutations are logically expected to have an ending
clinical expression on a given phenotype. However,
many of such clinical entities may have not even been
discovered as yet or at least not identified in the person
that has been sequenced. Therefore, presence of a single
mutation in one or more affected subject is no longer
indicative of its being specific and disease causing; the
biological significance of such specific mutations and
their individual causative nature may have to be shown
first. This is even more relevant when a specific mutation
is being reported for the first time in a new clinical entity.
However, if a significant number of individuals show one
or more mutations in the same gene and for the same
new phenotype, then the likelihood for involvement
of that gene in the etiology of that condition becomes
increasingly higher.
Over the last 25 years a variety of glaucoma families
and sporadic cases have been investigated by various
molecular genetics techniques but only a handful of
causative genes and a number of other specific gene
associations have been identified. [21] The first two
identified glaucoma genes, i.e. MYOC[22] and CYP1B1,[23]
have been extensively studied in juvenile‑onset and
congenital cases around the world and well‑proven to
be involved in a significant proportion of subjects.[21]
Moreover, these two genes have also been reported not
only in glaucoma, but also in a number of other ocular
disorders.[24‑27] This is indicative of the fact that mutations
in one specific gene may be responsible for various
subtypes of a common clinical entity or completely
different unrelated disorders. The study by Safari et al[8]
was an investigative approach to the same common goal.
Although a number of gene mutations have been
identified for other glaucoma subtypes (POAG, NTG,
PACG, PXFG)[21] and similarly, a group of other common
polymorphic DNA markers have been shown to be
associated with a specific glaucoma subtype,[21] none of
these as yet has been identified as a single gene or an
association that would be responsible for the majority
of a primary form of a given glaucoma subtype. This
in turn confirms the fact that a very large number of
genes (perhaps several hundred) may be involved in
the etiology of various forms of glaucoma and more
specifically for different forms of POAG and other types
of secondary glaucoma.
Given our limited success in understanding the
molecular and biochemical pathways that lead to
primary forms of various glaucoma subtypes, any
specific contribution that may shed light on such
challenging studies will be a welcome addition toward
this common goal. Given the anticipated large number of
genes that are expected to be involved in various forms
of glaucoma, it may be many more years of extensive
molecular investigation before we can have a better
96

understanding of this devastating clinical phenotype
that lead to blindness in many people around the world.
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